Overwatch Research Ltd

Overwatch Research Ltd is a specialized company focused on providing advanced data management solutions designed to optimize in vivo research studies for biotechnology firms. Founded in 2017 in Ireland, Overwatch Research Ltd develops cutting-edge platforms for managing in vivo studies. The company has engaged in three investment rounds, with the most recent being a Seed round in February 2022, where it raised GBP 2. 510 mn from investors including Frontline and SV Angel.

Overwatch was acquired by Benchling, Inc. in February 2022, a strategic move to enhance Benchling's cloud-native offerings. The company's headquarters is located in Dublin, Ireland, with no known subsidiaries or major pivots in business strategy. Overwatch Research Ltd offers Benchling In Vivo, a sophisticated platform designed to manage in vivo studies, emphasizing data capture, collaboration, and analytics.

This platform enables researchers to create repeatable study designs and incorporates randomization algorithms to mitigate selection bias. It supports data ingestion from various instruments and allows for real-time analysis and reporting, serving a diverse clientele of over 1,300 biotechnology companies worldwide, including both startups and established Fortune 500 firms. Benchling In Vivo generates revenue through subscription models, where clients pay for access to its services. These subscriptions are typically structured with tiered pricing, allowing organizations to choose packages that fit their research needs.

Transactions often occur through annual or multi-year contracts, which may include additional services like customized support and training, driven by the growing demand for data management solutions in the biotech sector. Following its acquisition by Benchling, Inc. in February 2022, Overwatch Research Ltd aims to expand its product offerings by integrating additional cloud-native in vivo solutions into Benchling's platform. The recent funding from the Seed round will facilitate the acceleration of product development and enhance the efficiency of products entering the clinical trial pipeline.

The company plans to target new markets across North America, Europe, and Asia to broaden its reach, leveraging its technology in biopharmaceuticals, agritech, and medical research sectors.